Respiratory
Cystic Fibrosis Acute Exacerbation
CF Trust UK — IV antibiotics matched to colonisation, airway clearance, nutrition, PERT, CFTR modulator continuation.
Source: CF Trust UK Antibiotic Management 2009 (review); ECFS
Step 1 of ~4
info
Recognise — Increased Symptoms
≥4 of: ↑ cough, ↑ sputum volume/purulence, dyspnoea, malaise, weight loss/anorexia, fever >38°C, ↓ FEV1 ≥10%, new infiltrate. Sputum culture mandatory before antibiotic change. Always involve regional CF centre. Verify all paediatric drug doses against BNFc if patient <18.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Elexacaftor / Tezacaftor / Ivacaftor · CFTR Triple Modulator (Cystic Fibrosis — F508del)
- Elexacaftor / Tezacaftor / Ivacaftor · CFTR Triple Modulator — Cystic Fibrosis
- Ivacaftor · CFTR Potentiator (Cystic Fibrosis — Gating Mutations)
- Ivacaftor · CFTR Potentiator — Cystic Fibrosis
- Tobramycin Inhalation · Inhaled Antibiotics — Bronchiectasis & Cystic Fibrosis
- Colistimethate Sodium (Inhaled) · Inhaled Antibiotics — Bronchiectasis & Cystic Fibrosis
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only. Always apply local guidelines and clinical judgement.